Navigation Links
NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Date:11/20/2007

eadquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference. TOPIGEN Pharmaceuticals Begins Patient Dosing in Phase 2 Trial of TPI 1020 in

COPD

Study to Assess Safety, Tolerability and Proof-of-Concept of TPI 1020

when Compared to Budesonide

MONTREAL, Nov. 20 /PRNewswire/ -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in developing products for respiratory disorders, today announced that the first patients have been dosed in a Phase 2 trial, designed to evaluate the safety, tolerability and proof-of-concept of inhaled TPI 1020 in patients suffering from chronic obstructive pulmonary disease (COPD). TPI 1020 is a novel, anti-inflammatory respiratory drug licensed from NicOx S.A. for respiratory indications.

The randomized, double-blind, placebo and active-controlled, multi-center, Phase 2 trial is expected to enroll approximately 50 evaluable patients. The primary endpoint of this six-week study is to assess the general safety and tolerability of TPI 1020 versus budesonide as well as efficacy of TPI 1020 versus budesonide on sputum neutrophils counts. Neutrophils are inflammatory cells that are important in the pathology of COPD.

Paul K. Wotton, Ph.D., President and Chief Executive Officer of TOPIGEN, commented, "TOPIGEN is committed to developing innovative medicines for respiratory diseases, such as asthma and COPD, where there is a need for more effective treatment options to improve prognosis and quality of life. We are delighted that pati
'/>"/>

SOURCE NicOx
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...wswire-FirstCall/--BostonScientificCorporation(NYS...ealthCareConference,December1-2. ,, RayElliott,...iveVicePresidentandChiefFinancialOfficer,willparti...ay,December1st,beginningatapproximately9:00a.m.E.T...etoallinterestedpartiesatBostonScientific,swebsite...
(Date:11/23/2009)....23/PRNewswire-FirstCall/--TransceptPharmaceutical...edtomeetwiththeU.S.FoodandDrugAdministration(FDA)o...egardingtheNewDrugApplication(NDA)for Intermezzo ...uslyannounced,theCompleteResponseLetter,receivedby...notapprovetheNDAinitspresentform.TheNDAseeksapprov...
(Date:11/23/2009)...23/PRNewswire-FirstCall/--Amgen(Nasdaq: AMGN )wash...PipelineandforBestNewDrugforNplate®(romiplost...lPipelineawardwaspresentedtoAmgenbyScripinrecognit...ecompany,spipeline,aswellasitsmixofcandidatesacros...elineisnotableforitsfocusonunmetclinicalneed. ,...
Breaking Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 3Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 4Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 5Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 6Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 1Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 3Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 4U S Doctors Treat Heart Attack With Mans Own Stem Cells 50463 1U S Doctors Treat Heart Attack With Mans Own Stem Cells 50463 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 1FDA Advisers Urge Smaller Doses of Acetaminophen 50458 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 3
...s Activity in Multiple Myeloma and Mantle Cell Lym...esis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ...in multiple myeloma and mantle cell lymphoma. Data...Multiple Myeloma Research,Consortium (MMRC) and wi...er were presented at the Annual Meeting of the Ame...
...cal data presented at the 60th Annual Meeting of t... in Chicago, SMYRNA, Ga., April 16 UCB presented...of Phase II and III double-blind, randomized,place...mide for the,treatment of diabetic neuropathic pai...nual Meeting of the American Academy of Neurology ...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 2Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 3Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research 4Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 2Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 3
(Date:11/23/2009)...ildren who don,t access health care from the same ...ntly more likely to have unmet health care needs c...blished in the journal Pediatrics . , Studies ...nd delivery of quality health care for children, t... debates about health insurance reform, much of th...
(Date:11/23/2009)...g chemo deal with insomnia, study shows , ...nd sleep disorders affect more than three-quarters...e nearly three times higher than that of the gener... is more common in younger patients and in those w...chester Medical Center researchers, who assessed s...
(Date:11/23/2009)...tyBanksin Washington D.C. , NewYorkCity , ...EconomicGrowthandRevitalization ,, WASHINGTON,...n,sleadingproviderofdialysisservices,todaywaslaude...ora$1millioninvestmentinIndustrialBankaspartofanin..., DaVita,sinvestmentinWashington,D.C.ispartofthed...
(Date:11/23/2009)...rogramSupportsFutureLeadersinSTEMFields ,, Sc...a n ceS c holars.org ,, WASHINGT...ucancountusin.Withourcommunity,foundation,andcorpo...Innovate,"saidAdolphP.Falcon,SeniorVicePresidentof...gaWhiteHousemeetingtodaywherePresidentObamaannounc...
(Date:11/23/2009).../PRNewswire-USNewswire/--SouthamptonHospitalannoun...ntofundanewEmergencyDepartment.Thegiftisthelargest...mostdoubletheexistingspaceandgreatlyexpanditsdeliv...ForkofLongIsland. ,, ScheduledforcompletionbyMa...illprovideacentralizedtraumanurses,stationandtriag...
Breaking Medicine News(10 mins):Health News:Children who lack continuity with a regular health care provider miss needed services 2Health News:Children who lack continuity with a regular health care provider miss needed services 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:Southampton Hospital Receives $5 Million Gift for New Emergency Department 2
...oin Nationwide Campaign to Close the Gaps that Ma... Women of Color, SACRAMENTO, Calif., Jan. 17 Tod...ors from the seven California Affiliates of,Susan ...east cancer policies at events which included ligh...
...dge of health risks posed by long-term use , ...l phone technology and use continues to expand and...ut the potential health risks associated with long...high occupational exposure -- the report authors c...
...California premiere,of BODY WORLDS 3 & The Story o... March 14, 2008 and runs through September 7, 2008...ecimens including whole body,plastinates not seen .../DC11822 ), The Science Center hosted the US pre...
...munosyn,Corporation (OTC Bulletin Board: IMYN) ann...of of Concept Trial" for the biopharmaceutical SF-... treatment of Diabetic Ulcers., The Board of Immu...argest shareholder. Argyll Biotechnologies is the,...
...ute launched a new one-of-a-kind service for the r...ation Microarray Service (MIM) enables the rapid i...ples. The first service offering, Human Oral Micro...bacterial associations in health vs. disease, moni...
...ently discovered function of a multi-faceted trans...n both normal cells and cancer stem cells. Two sep...ary 18th issue of Molecular Cell, provide insight ...ion that is required for full activity of nuclear ...
Other Medicine News:Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 2Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 3Health News:Susan G. Komen for the Cure, State Lawmakers, Breast Cancer Survivors, Celebrities and Activists Call on Legislature to Strengthen Breast Cancer Screening Program for Underserved Women 4Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 2Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 3Health News:BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008 4Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Forsyth launches 1-of-a-kind core service to enable rapid identification of bacterial samples 2Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3
Kronos LV-T Cardiac Resynchronization Therapy Defibrillator (CRT-D) System
...Medicomps revolutionary technology provides full p...or to incorporate true Artifi cial Intelligence, w...ity, in the background, on each device. The Diogen...rdiac activity based on rate, rhythm, morphology, ...
...he new, hydrophilic PressureWire Certus guidewire ... cardiology tool for guiding intervention in patie...nal Flow Reserve (FFR)., ,Enhanced handling pr...ty with a strengthened core wire linking tip to ta...
Sound Pro Combination Table
Medicine Products: